NeoImmuneTech Reveals 'NT-I7' Combination Study Abstract at AACR

[Asia Economy Reporter Chunhee Lee] NeoImmuneTech disclosed on the 10th two preclinical study abstracts presented at the American Association for Cancer Research (AACR) regarding the combination of the immune-oncology drug NT-I7 (active ingredient 'Epineptakin Alpha'), which induces T cell expansion, with a T cell activator and a T cell inhibitory checkpoint inhibitor, respectively.

The first study topic is the improved anticancer efficacy when combining NT-I7 with the T cell activator IL-2 (hIL-2/TCB2c), and the second study topic is the enhanced anticancer efficacy when combining NT-I7 with T cell inhibitory checkpoint inhibitors, specifically TIGIT inhibitors and VEGF inhibitors.

Recently, global big pharma companies that have successfully commercialized PD-(L)1 inhibitors are developing follow-up pipelines including IL-2, TIGIT inhibitors, and VEGF inhibitors, aiming to enhance therapeutic effects through various combination therapies. The company explained that in this context, the preclinical study results showing that NT-I7 can have synergistic therapeutic effects when combined with immune-oncology drugs other than PD-(L)1 inhibitors could serve as valuable data for future global technology licensing and commercialization.

The detailed poster on the preclinical combination studies of NT-I7 will be presented at AACR on the 13th of next month (local time).

This content was produced with the assistance of AI translation services.